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Induction	chemotherapy	with	standard	cytotoxic	
chemotherapeutic	agents	produces	complete	remis‑
sion	in	the	majority	of	the	patients	with	acute	myelo‑
geneous	leukemia	(AML).	Unfortunately,	most	of	these	
patients	relapse	and	eventually	die	from	the	disease.	
Efforts	to	 increase	the	overall	and	disease‑free	sur‑
vival	rates	in	AML	are	focused	on	improving	the	effi‑
cacy	of	post	remission	consolidation	by	administering	
dose‑intensified	cytotoxic	chemotherapeutic	agents	
alone	or	combined	with	autologous	or	allogeneic	stem	
cell	support	[6].
Besides	the	antiangiogenic	and	immunomodula‑
tory	effects	of	thalidomide,	it	acts	directly	by	inducing	
apoptosis	or	cell	cycle	block	at	G1	phase,	in	multiple	
myeloma	(MM)	cell	lines	and	in	MM	cells	that	are	re‑
sistant	to	melphalan,	doxorubicin,	and	dexamethasone	
[5].	Furthermore,	 thalidomide	has	been	reported	 to	
have	antitumor	activity	via	 induction	of	apoptosis	 in	
AML	cells	[12],	whereas	single	agent	thalidomide	has	
not	been	regarded	as	an	optimal	choice	of	therapy	for	
salvaging	patients	with	poor	prognosis	or	refractory	
AML	in	clinical	studies	[14].
Early	 studies	have	shown	 that	most	AML	blasts	
express	cytokine	receptors	for	myeloid	growth	factors.	
Moreover,	granulocyte‑macrophage	colony‑stimula‑
ting	factor	(GM‑CSF),	interleukin	3,	and	granulocyte	
colony‑stimulating	 factor	 (G‑CSF)	 increase	colony	
formation	and	 induce	proliferation	 in	up	 to	80%	of	
primary	AML	blasts.	In	addition,	signals	that	stimulate	
cell	cycle	progression	(e.	g.	c‑myc)	inhibit	differentia‑
tion,	while	many	agents	with	differentiating	activity	are	
cytostatic	[10].	Thus,	inhibition	of	cell	cycling	may	be	a	
permissive	or	inductive	requirement	for	differentiation.	
Matsui	et	al.	[8]	have	demonstrated	that	combination	
of	clinical	applicable	cell	cycle	inhibitors	(e.	g.	phenyl‑
butyrate,	hydroxyurea	and	bryostatin‑1)	with	growth	
factors	 induces	 terminal	 favorable	differentiation	of	
treatment‑resistant	myeloid	leukemias.
To	 further	 investigate	 the	antileukemic	and	dif‑
ferentiation	potential	of	 thalidomide,	we	studied	 its	
differentiating	and	proapoptotic	effects	in vitro	toward	
HL‑60	cells	alone	or	in	combination	with	GM‑CSF.
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rial	Sloan‑Kettering	Cancer	Center,	USA).	HL‑60	cells	
were	maintained	in	RPMI	1640	medium	(Sigma,	USA)	
supplemented	with	10%	heat‑inactivated	 fetal	 calf	
serum	(Sigma,	USA),	and	2	mM	L‑glutamine	(Sigma,	
USA),	100	μg/mL	streptomycin	and	100	U/mL	penicillin	
(Sigma,	USA)	at	37	°C	in	a	5%	CO2	atmosphere.
Reagents. Thalidomide	was	kindly	provided	by	
Celgene	(USA).	Leucomax	400	μg	(Novartis,	Turkey)	
was	used	as	a	source	of	GM‑CSF.	A	stock	solution	of	
GM‑CSF	was	prepared	in	phosphate	buffered	saline	
(PBS)	(Sigma,	USA),	pH	7.4	and	filter‑sterilized	using	
a	0.22	µm	filter.	Thalidomide	was	dissolved	 in	0.1%	
DMSO	(Sigma,	USA)	and	diluted	 in	culture	medium	
(0.01	to	100	µM)	immediately	before	use.
MTT assay. The	MTT	 (Biological	 Industries,	 Is‑
rael)	cell	viability	assay	was	performed	as	previously	
described	[15],	and	the	absorbance	at	570‑nm	was	
recorded	using	a	96‑well	microplate	reader	(Bio‑Tek	
Instruments	Inc.,	USA).	Each	experiment	was	repeated	
3	times.
In	some	studies,	target	HL‑60	cells	were	plated	at	
a	density	of	5	x	104	per	well	in	24‑well	plates	(Costar,	
USA)	with	media	containing	200	U/ml	GM‑CSF	 for	
increasing	time	of	incubation	to	determine	the	prolife‑
rative	effect	of	GM‑CSF.	In	each	separate	experiment,	
following	incubation,	cells	were	harvested,	suspended	
in	PBS	and	cell	number	determined	using	haemocy‑
tometer	(Bright‑line,	Hausser	Scientic,	USA).
Cell cycle analysis, and determination of apop-
tosis.	For	cell	cycle	analysis,	the	cells	were	washed	
once	 in	PBS	and	 then	stained	with	PI	using	a	com‑
mercial	kit	(Cycle	Test	Plus	DNA	Reagents	Kit;	Becton	
Dickinson,	USA)	for	10	min	at	4	°C	in	the	dark,	and	the	
cells	were	analyzed	with	a	flow	cytometer	(FACScan;	
Becton	Dickinson,	USA).	Analysis	was	carried	out	on	
three	separate	experiments.
To	assess	apoptosis,	cells	were	seeded	in	a	24‑well	
plate	and	treated	with	thalidomide,	GM‑CSF,	or	their	
combination	for	48	h,	and	then	the	cells	were	labeled	
with	FITC‑conjugated	annexin‑V	(Becton	Dickinson,	
USA)	 and	 detected	 by	 FACScan	 flow	 cytometry.	
Treated	cells	were	dissociated	and	washed	 twice	 in	
a	binding	buffer	(10	mM	HEPES,	140	mM	NaCl	and	
2.5	mM	CaCl2).	Cells	were	 then	 labeled	with	5	μL	
Annexin‑V‑FITC/50	μL	binding	buffer	for	15	min	in	the	
dark	and	at	room	temperature.	 Immediately	prior	to	
analysis	on	the	flow	cytometer,	the	samples	were	also	
labeled	with	250	μL	of	a	10	mg/ml	stock	PI	solution.	
Analysis	was	carried	out	in	triplicate.
Determination of differentiation markers.	The	
extent	of	monocyte	differentiation	induced	in	HL‑60	
cells	by	thalidomide	(20	μM)	with	or	without	GM‑CSF	
(200	U/ml)	 after	 48	 h	 incubation	was	determined	
by	monitoring	the	CD14,	CD11b	and	CD11c	surface	
markers	by	flow	cytometry.	Aliquots	of	1	x	106	HL‑60	
cells	were	harvested	at	 various	 time	points,	centri‑
fuged,	and	washed	twice	with	1	x	PBS.	The	cell	pellet	
was	resuspended	in	100	μL	PBS;	and	20	μL	of	mono‑
clonal	antibodies	specific	for	CD14,	CD11b	and	CD11c	
(Becton	Dickinson,	USA)	were	added,	and	the	mixture	
was	incubated	in	the	dark	at	2–8	°C	for	15–30	min.	The	
excess	antibody	was	washed	off	with	1	x	PBS,	and	the	
pellet	was	resuspended	in	500	μL	of	1	x	PBS.	The	cells	
were	analyzed	by	FACScan	flow	cytometer.	
Statistical analysis. Student’s	 two‑tailed	 t‑test	
was	used	to	determine	statistical	significance	of	de‑
tected	differences.	A	value	of	p <	0.05	was	considered	
statistically	significant.
results and discussion
As	shown	in	Fig.	1,	a,	MTT	assay	revealed	significant	
antiproliferative	effect	of	 thalidomide	against	HL‑60	
cells	after	48	and	72	h	of	incubation	with	the	agent	only	
if	its	concentration	is	higher	than	50	µM	(p < 0.01).
fig. 1. Effect	of	thalidomide	(a)	and	200	U/ml	GM‑CSF	(b)	on	
proliferation	of	HL‑60	cells.	a: HL‑60	cells	were	 incubated	with	
thalidomide	for	48	(‑‑)	and	72	h	(‑‑). Results	are	expressed	
as	control	or	absolute	cell	numbers	(%).	The	data	are	presented	
as	Mean	±	SD	of	three	separate	experiments	
*Statistically	significant values	compared	with	control	(p	<	0.01).
Since	 thalidomide	 has	 been	 reported	 to	 have	
antitumor	activity	 [12],	we	studied	 its	 influence	on	
programmed	cell	death	in	HL‑60	cells.	Apoptotic	cells	
were	detected	as	a	significant	sub‑G1	shoulder	(Mean	
32.7	±	3.5%;	p <	0.001)	representing	hypodiploid	cells	
in	cultures	that	had	been	treated	with	50	µM	thalido‑
mide,	but	not	in	untreated	cells	(Table	1).	Thalidomide	
(20	µM)	inhibited	the	cells	proliferation	associated	with	
cell	cycle	arrest	at	G1	but	without	significant	cytotoxicity	
as	assessed	by	MTT	assay	(Fig.	1,	a)	or	flow	cytometric	
analysis	of	apoptosis	(Table	1).	The	percentage	of	apop‑
totic,	necrotic,	and	viable	cells	after	single	or	combined	
treatment	was	evaluated	by	Annexin‑V	binding.	Repre‑
sentative	data	are	shown	in	Table	2.	A	minimal	apoptotic	
rate	was	observed	with	 low	dose	 thalidomide	when	
compared	to	untreated	cells.	In	contrast,	treatment	of	
cells	with	high	dose	thalidomide	(50	µM)	dramatically	
augmented	apoptosis	concordant	with	cell	cycle	analy‑
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sis	data.	Thalidomide	alone	has	not	displayed	enhanced	
CD14,	CD11b	and	CD11c	expression	(Fig.	2).
Table 1. Analysis of cell cycle distribution of HL-60 cells incubated with 
thalidomide, GM-CSF, or their combination for 48 h. Results are presented 
as % cells and represent the mean ± SD of three separate experiments
Cell 
cycle 
phase
Control
Thalido-
mide
(20 µM)
Thalido-
mide
(50 µM)
GM-CSF
(200 U/ml)
Thalidomide  
(20 µM) + 
GM-CSF 
(200 U/ml)
G0-G1 28.4 ± 1.4 48.2 ± 6.2 22.3 ± 1.2 29.1 ± 2.2 49.2 ± 7.1
S 65.2 ± 3.4 34.5 ± 2.3 34.8 ± 2.7 68.7 ± 4.1 38.7 ± 4.2
G2-M 6.4 ± 0.9 16.2 ± 1.3 10.2 ± 1.2 2.2 ± 0.4 12.1 ± 1.7
Sub-G1
(apop-
tosis)
1.1 ± 0.2 32.7 ± 3.5
Table 2. Flow cytometric analysis of apoptotic rate of HL-60 cells incu-
bated for 48 h with thalidomide, GM-CSF, or their combination
Staining Control
Thalido-
mide
(20 µM)
Thalido-
mide
(50 µM)
GM-CSF
(200 U/ml)
Thalidomide 
(20 µM) +
GM-CSF (200 
U/ml)
Annexin  
V-/PI-,  
viable cells (%)
88.5 70.9 9.5 88.8 91.2
Annexin  
V+/PI– early 
apoptotic cells 
(%) 
3.8 7.2 2.3 1.5 2.3
Annexin  
V+/PI+,  
late apoptotic 
cells (%)
2.5 13.3 80.6 3.4 2.7
Annexin V–/
PI+, necrotic 
cells (%)
5.2 8.6 7.6 4.5 4.5
fig. 2. Effects	of	thalidomide	and	GM‑CSF	on	surface	antigen	
expression	on	HL‑60	cells.	Cells	were	incubated	for	48	h	in	the	
absence	(Control)	or	presence	of	20	μΜ	thalidomide	with	or	without	
200	U/ml	GM‑CSF	and	then	assessed	for	the	surface	expression	
of	CD14,	CD11b	and	CD11a	by	flow	cytometry.	Results	represent	
means	of	three	separate	experiments;	bars,	SD.	P	was	determined	
for	the	comparison	of	all	treatment	groups
*Statistically	significant values	compared	with	control	(p	<	0.01).
Enhanced	 terminal	 differentiation	 of	 leukemic	
cells	resulting	from	the	combined	use	of	growth	fac‑
tors	and	pharmacological	differentiating	agents	other	
than	thalidomide	has	been	described	[16].	A	study	by	
Matsui	et	al.	[8]	has	shown	that	neutralizing	antibod‑
ies	directed	against	GM‑CSF,	completely	inhibited	the	
activity	of	all	differentiating	agents	tested.	These	data	
suggest	 that	pharmacological	differentiating	agents	
require	 the	additional	 activity	of	growth	 factors	 for	
inducing	 tumor	cell	 terminal	differentiation.	An	ad‑
vantage	of	using	thalidomide	is	its	additional	effect	to	
the	neutralizing	effect	of	some	proinflammatory,	pro‑
apoptotic	cytokines	[7],	whereby	thalidomide	is	also	
known	to	induce	apoptosis	and	cell	cycle	block	at	G1	
phase	in	leukemic	cells	[12].	However,	the	stated	dif‑
ferentiating	effect	of	thalidomide	by	affecting	cell	cycle	
could	not	specifically	be	considered	attributable	to	the	
drug	in	our	study.	The	other	clinically	applicable	cell	
cycle	inhibitors	(i.	e.	phenylbutyrate,	hydroxyurea	and	
bryostatin)	in	combination	with	lineage	specific	growth	
factors	may	induce	tumor	cell	differentiation.
The	association	between	cell	cycle	 inhibition	and	
cellular	differentiation	is	well	recognized;	the	induction	of	
differentiation	of	both	normal	and	malignant	cells	is	as‑
sociated	with	cell	cycle	inhibition	that	is	mediated	by	the	
cycle	dependent	kinase	(cdk)	activity	and	the	induction	
of	cdk	inhibitor	p21	[13].	The	inhibition	of	cell	cycle	may	
play	an	important	role	in	the	activity	of	pharmacological	
differentiating	agents	where	most	agents,	such	as	ATRA,	
vitamin	D,	share	this	biological	property	despite	interact‑
ing	with	a	diverse	array	of	cellular	targets	[9].
Although	HL‑60	cells	express	functional	GM‑CSF	
receptors	[11],	GM‑CSF	alone	had	no	significant	effect	
on	the	differentiation	of	cells	as	assessed	by	analysis	of	
CD14,	CD11b	and	CD11c	expression	(Fig.	2).	However,	
GM‑CSF	alone	had	a	significant	effect	on	the	growth	
of	HL‑60	cells	compared	to	control	(Fig.	1,	b).	The	ad‑
dition	of	GM‑CSF	to	thalidomide	displayed	enhance‑
ment	CD14,	CD11b	and	CD11c	expression	on	HL‑60	
cells	compared	to	the	control	(p <	0.01)	(Fig.	2).	But	
GM‑CSF	and	thalidomide	combination	has	not	induced	
apoptosis	(Table	1).
Lineage‑specific	growth	 factors,	such	as	G‑CSF	
and	GM‑CSF,	have	pleitropic	effects	on	both	malignant	
and	normal	cells	with	enhanced	proliferation,	cell	sur‑
vival	promotion	resulting	in	favorable	differentiation	and	
desired	functional	activity	of	myeloid	cells.	The	stimula‑
tory	effects	of	myeloid	growth	factors	on	leukemic	cell	
growth	may	predominate	in	most	settings;	however	it	
has	been	shown	previously	that	GM‑CSF	preferentially	
enhances	the	differentiation,	rather	than	proliferation,	
of	malignant	progenitors	[4].	This	could	be	a	result	of	
an	abnormal	function	or	expression	of	G‑CSF/GM‑CSF	
receptor‑associated	signal	transduction	proteins	such	
as	Jak	kinases	or	STAT	transcription	factors	[3].	In	fact,	
it	has	been	reported	that	Jak2	kinase	is	necessary	for	
STAT	activation	by	GM‑CSF	receptor	and	 is	 required	
for	cellular	proliferation	[1,	2].	Therefore,	the	Jak‑STAT	
pathway	might	be	critical	for	the	anti‑apoptotic	activity	
of	GM‑CSF	in	HL‑60	cells	treated	with	a	combination	
of	thalidomide	and	GM‑CSF	in	our	study.
In	conclusion,	we	have	shown	that	blocking	the	cell	
cycle	by	 thalidomide	at	G1	augmented	growth	 factor	
driven	differentiation	of	HL‑60	cells.	Our	current	data	
indicate	that	the	full	induction	of	terminal	differentiation	
requires	cell	cycle	inhibition	by	any	agent	combined	with	
lineage	specific	growth	factors,	and	the	combination	of	
GM‑CSF	and	thalidomide	may	be	used	in	the	clinical	
practice	for	the	management	of	acute	promyelocytic	
or	differentiation‑inducible	leukemias.
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ГМ-КСФ в Сочетании С талидоМидоМ вызывает 
диФФеренцировКу КлетоК линии hl-60 СтроГо 
проМиелоцитарноГо лейКоза человеКа
Цель: изучить эффект гранулоцитарно-макрофагального колониестимулирующего фактора (ГМ-КСФ) в сочетании 
с талидомидом на индукцию апоптоза и дифференцировку клеток острого промиелоцитарного лейкоза линии HL-60 
in vitro. Методы: для оценки пролиферации и жизнеспособности клеток HL-60 применяли MTT анализ, для изучения 
клеточного цикла — окраску пропидиум бромидом и проточную цитометрию. Для оценки апоптоза клетки линии HL-60 
обрабатывали талидомидом, ГМ-КСФ, и совместно талидомидом и ГМ-КСФ в течении 48 ч, и затем метили анекси-
ном, конъюгированным с FITC, и анализировали с помощью проточной цитометрии. Результаты: талидомид в высоких 
концентрациях ингибирует пролиферацию клеток HL-60 и вызывает апоптоз. В сочетании с ГМ-КСФ в течение 3 дней 
талидомид в низкой концентрации индуцировал терминальную дифференцировку клеток HL-60, о чем свидетельствовало 
появление экспрессии дифференцировочных антигенов на поверхности клеток. Выводы: применение талидомида в низкой 
концентрации в сочетании с ГМ-КСФ вызывает терминальную дифференцировку клеток HL-60.
Ключевые слова: талидомид, ГМ-КСФ, HL-60, дифференцировка, апоптоз.
